Inverness, Elbowing In on Beckman, Makes Unsolicited Bid for Biosite; Biosite 'Evaluating' Offer | GenomeWeb
NEW YORK (GenomeWeb News) — Beckman Coulter has a rival trying to foil its planned $1.6-billion acquisition of Biosite.
 
Biosite said today it is reviewing an unsolicited acquisition offer from Inverness Medical Innovations to acquire the diagnostics company at a higher price than Beckman Coulter offered late last month.
 
Beckman has responded today by stating its “firm commitment” to buy the company in the next 30 days.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.